Business Context and Reporting Period
Company: EyePoint Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2019
Event: Entry into a new Term Loan Agreement and termination of an existing Credit Agreement.
Key Financial Metrics and Debt Structure
New Term Loan Agreement (CRG Servicing LLC):
- Total Facility Size: Up to $60 million.
- Initial Advance: $35 million on the Closing Date.
- Optional Advances: Up to $15 million at Company option by June 30, 2019.
- Contingent Advance: Up to $10 million if product revenue from YUTIQ and DEXYCU reaches $25 million in any consecutive three-month period ending on or prior to March 31, 2020.
- Maturity Date: December 31, 2023.
- Interest Rate: 12.5% per annum (2.5% may be paid in-kind).
- Fees: 1.5% upfront fee; 6% exit fee.
- Prepayment Premiums: 10% (if prepaid by Dec 31, 2019), 5% (by Dec 31, 2020), 3% (by Dec 31, 2021); 0% thereafter.
Terminated Credit Agreement (SWK Funding LLC):
- Outstanding Principal Repaid: $20.0 million.
- Accrued Interest Paid: Approximately $970,000.
- Exit/Prepayment Fees Paid: 12% total (6% exit fee + 6% voluntary prepayment fee).
Use of Proceeds: Repayment of existing indebtedness, transaction fees, and general working capital.
Material Changes Versus Prior Period
The Company replaced its existing $20 million senior secured term loan with SWK Funding LLC with a new, larger facility of up to $60 million from CRG Servicing LLC. This transaction increased the Company's potential debt capacity and extended the maturity date to December 31, 2023 (the prior loan matured March 28, 2023). The interest rate structure shifted from a variable LIBOR-based rate (LIBOR + 10.50% with a 1.5% floor) to a fixed 12.5% rate with a partial pay-in-kind option.
Guidance, Covenants, and Risks
Financial Covenants:
- Liquidity: Must maintain liquidity exceeding the greater of $5 million or minimum cash balances required by other permitted debt.
- Minimum Product Revenue (YUTIQ and DEXYCU):
- 2019: $15 million
- 2020: $45 million
- 2021: $80 million
- 2022: $90 million
Other Covenants: Standard affirmative and negative covenants limiting additional debt, liens, investments, acquisitions, mergers, asset dispositions, and dividends.
Risks and Contingencies:
- Default Risk: Failure to meet revenue covenants or liquidity requirements constitutes an event of default, allowing acceleration of the loan.
- Collateral: The loan is secured by a pledge of substantially all assets of the Company and its guarantors.
- Prepayment Costs: Significant prepayment premiums apply if the loan is retired early (up to 10% in the first year).
Investor Verification Checklist
- Verify the Company's current cash balance to ensure compliance with the $5 million minimum liquidity covenant.
- Monitor quarterly revenue reports for YUTIQ and DEXYCU to assess progress toward the $15 million 2019 revenue covenant.
- Review the full text of the Term Loan Agreement (Exhibit 10.1) for specific definitions of "liquidity" and "product revenue."
- Confirm the exact amount of the initial $35 million advance and the timing of any subsequent optional draws.
- Assess the impact of the 12.5% interest rate (including potential PIK interest) on future cash flow projections.